SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceedonly a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) — …